Abstract: A transdermal electrotransport drug delivery system with hydratable reservoir and method for drug delivery to an individual. The system has a hydratable reservoir with impedance measurement means for determining level of hydration in the reservoir.

Abstract: A transdermal electrotransport drug delivery system to an individual. The system has a liquid imbibing polymer with carboxyl groups available for noncovalently associating with a cationic drug. The liquid imbibing polymer is applicable for imbibing liquid before the device is deployed on a patient for electrotransport drug delivery.

Abstract: The present invention provides methods and devices for the electrotransport delivery of beneficial agents that utilize polymer electrolyte matrices as drug reservoirs. In certain aspects of the invention, the beneficial agents are hydrolytically unstable, and methods are provided for enhancing the stability of the hydrolytically unstable beneficial agents during long-term storage of devices for the electrotransport delivery of the hydrolytically unstable beneficial agents and during electrotransport delivery of the hydrolytically unstable beneficial agents.

Abstract: A cathode for an electrotransport drug delivery system for the delivery of anionic drugs. The cathode has a composite structure that contains an electroactive species that upon reduction does not generate any gas or an anion that competes with the anionic drug during electrotransport.

Abstract: A system and method for transdermally delivering a biologically active agent comprising one or more electrodes having stratum corneum-piercing projections and a circuit that delivers an electrical signal to the electrodes to electroporate a cell membrane. Preferably, the system is configured to generate homogeneous electrical fields and, more preferably, to generate spherically or semispherically symmetrical electric fields. Methods of the invention include applying a first electric signal to facilitate transdermal transport of the agent and applying a second electric signal to facilitate intracellular transport of the agent.

Abstract: A device for transdermally delivering an anticoagulant agent by electrotransport. Preferably, the anticoagulant comprises a benzamidine or a naphthamidine derivative. A particularly preferred benzamidine derivative is a 2-[3-[4-(4-piperidinyloxy)anilino]-1-propenyl]benzamidine derivative. The devices are configured to maintain a plasma concentration of 20-80 ng/mL or providing a flux in the range of approximately 20-40 mg/day. Suitable current densities include 0.050 and 0.10 mA/cm2. Methods of the invention include delivering the anticoagulants to precisely maintain the desired plasma concentrations. The invention also comprises treating thromboembolic disease and inhibiting Factor Xa.

Abstract: The present invention provides methods for preparing compositions for use in electrotransport delivery systems that comprise providing a drug solution comprising drug ions and associated counterions; adjusting the pH of the drug solution by contacting the drug solution with a first ion exchange material; separating the first ion exchange material from the pH-adjusted drug solution; adding the pH-adjusted drug solution to a reservoir of an electrotransport delivery system; and contacting the pH-adjusted drug solution with a second ion exchange material.

Abstract: A system and method for transdermally delivering a vaccine to a patient including an iontophoresis delivery device having a donor electrode, a counter electrode, and electric circuitry for supplying iontophoresis energy to the electrodes, and a non-electroactive microprojection member having a plurality of stratum corneum-piercing microprojections extending therefrom. The vaccine can be contained in a hydrogel formulation in an agent reservoir disposed proximate the donor electrode, in a biocompatible coating that is disposed on the microprojections or in both.